<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322008</url>
  </required_header>
  <id_info>
    <org_study_id>Anti-TNF, IBD</org_study_id>
    <nct_id>NCT02322008</nct_id>
  </id_info>
  <brief_title>Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice</brief_title>
  <official_title>Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regionshospitalet Viborg, Skive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Can genetic markers be used to predict anti-TNF response? A cohort was established to
      identify SNPs associated with anti-TNF therapy in patients with inflammatory bowel disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3-step scale</measure>
    <time_frame>22 weeks</time_frame>
    <description>Best response within 22 weeks</description>
  </primary_outcome>
  <enrollment type="Actual">1035</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infliximab and adalimumab</intervention_name>
    <description>In this retrospective, observational study, no interventions were undertaken by the researchers.</description>
    <other_name>remicade and humira, anti-TNF</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1035 patients with CD or UC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CD or UC, treated with anti-TNF

        Exclusion Criteria:

          -  Missing data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Steffen Bank</investigator_full_name>
    <investigator_title>M.sc, phd</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

